Key facts
- This page summarizes Pierre Sargis Sayad's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 31 Aug 2026, 20:15.
Pierre Sargis Sayad - 31 Aug 2026 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- FENC
- Reported as of
- 31 Aug 2026
- Net transaction value
- -$146,160
- SEC form
- 4
- Accepted by SEC
- 31 Aug 2026, 20:15:24 UTC
- Prior SEC filing
- 03 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pierre Sayad
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pierre Sargis Sayad filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 31 Aug 2026.
Change
- Previous filing in this sequence was filed on 03 Aug 2026.
- Current net transaction value: -$146,160.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002043395
Primary reporting owner
Sayad Pierre Sargis
- Relationship
- Chief Medical Officer
- Address
- C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK
- Signature
- /s/ Pierre Sayad
- Signature date
- 31 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FENC
transaction
Common Shares
Award
- Transaction value
- Shares
- +168
- Change %
- +0.79%
- Price
- $0.000000*
- Shares after
- 21,519
- Date
- 31 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
FENC
transaction
Common Shares
Sale
- Transaction value
- $146,160
- Shares
- -12,000
- Change %
- -56%
- Price
- $12.18
- Shares after
- 9,519
- Date
- 31 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares released from restriction from shares awarded 3/28/2025.
Footnote F2
Represents sale of previously vested restricted shares and vested performance shares.